Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Malignant Lymphoma

Free Subscription 23.02.2026 2 Blood 1 BMC Neurol 2 Br J Haematol 1 Cancer 1 Eur J Haematol 1 Exp Cell Res 3 Leukemia 1 Mod Pathol 1 Oncology (Williston Park)

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Blood

1. DOWLING MR, Cliff ERS, Jeffrey A, Cashion C, et al
   Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.
   Blood. 2026 Feb 17:blood.2025032307. doi: 10.1182/blood.2025032307.
   PubMed         Abstract available
   
   
2. STEWART J, Damania B
   Withaferin A inhibits EBV-driven lymphomagenesis through multiple mechanisms, including EBNA1 degradation.
   Blood. 2026;147:848-862.
   PubMed         Abstract available
   
   

   
   BMC Neurol

3. ZHANG M, Liu X, Cheng S, Ruan Y, et al
   A case report: primary central nervous system lymphoma misdiagnosed as neuromyelitis optica.
   BMC Neurol. 2026 Feb 16. doi: 10.1186/s12883-026-04711.
   PubMed        
   
   

   
   Br J Haematol

4. POUTHIER M, Garnier N, Leruste A, Rigaud C, et al
   Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real-world study.
   Br J Haematol. 2026 Feb 17. doi: 10.1111/bjh.70379.
   PubMed         Abstract available
   
   
5. ZADRO A, Arribas A, Colombo MV, Cannas E, et al
   A high-throughput bone marrow 3D co-culture system to study resistance to BCR signalling targeted agents in B-NHL.
   Br J Haematol. 2026;208:716-721.
   PubMed         Abstract available
   
   

   
   Cancer

6. TANG L, Cai D, Yan X, Mo W, et al
   Second-line chimeric antigen receptor T-cell therapy versus standard of care in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis.
   Cancer. 2026;132:e70317.
   PubMed         Abstract available
   
   

   
   Eur J Haematol

7. TIDSWELL R, Owen C, Shafey M, Perry S, et al
   Real-World Selection of Venetoclax-Obinutuzumab Versus BTK Inhibitor Therapy for Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
   Eur J Haematol. 2026 Feb 16. doi: 10.1111/ejh.70137.
   PubMed         Abstract available
   
   

   
   Exp Cell Res

8. JIANG W, Ren N, Wang T, Man X, et al
   KPT-8602 combined with IFN-gamma released ZBP1-PANoptosome to inhibit the progression of primary central nervous system lymphoma.
   Exp Cell Res. 2026 Feb 18:114946. doi: 10.1016/j.yexcr.2026.114946.
   PubMed         Abstract available
   
   

   
   Leukemia

9. MADIOT C, Bellanger C, Dousset C, Decombis S, et al
   CD40/PI3K/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival.
   Leukemia. 2026 Feb 19. doi: 10.1038/s41375-026-02894.
   PubMed         Abstract available
   
   
10. FILIP D, Litzmanova K, Michaelou A, Kledus F, et al
    Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma.
    Leukemia. 2026 Feb 19. doi: 10.1038/s41375-026-02868.
    PubMed         Abstract available
    
    
11. LANDSBURG DJ, Musoke N, Gentile C, Brooks TR, et al
    Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma.
    Leukemia. 2026 Feb 17. doi: 10.1038/s41375-026-02870.
    PubMed        
    
    

    
    Mod Pathol

12. HELIAS-RODZEWICZ Z, Ungureanu IA, Kemps PG, Donadieu J, et al
    ALK(ATI) Drives Nuclear Anaplastic Lymphoma Kinase (ALK) Expression in Histiocytic Neoplasms Without ALK Fusions.
    Mod Pathol. 2026;39:100956.
    PubMed         Abstract available
    
    

    
    Oncology (Williston Park)

13. LYMPHOMA RESEARCH FOUNDATION L
    2025 Report on the Mantle Cell Lymphoma Scientific Consortium and Workshop Hosted by the Lymphoma Research Foundation.
    Oncology (Williston Park). 2026;40:16-32.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum